Le Lézard
Classified in: Health, Business
Subjects: EARNINGS, CALENDAR OF EVENTS, Conference Calls/ Webcasts

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update


MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT.

Theratechnologies will also provide further information on the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Company's supplemental Biologics License Application for the F8 formulation of tesamorelin.

The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc, Senior Vice President and Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below.

CONFERENCE CALL INFORMATION
Conference Call DateFebruary 21, 2024
Conference Call Time8:30 a.m. EDT
Webcast linkhttps://edge.media-server.com/mmc/p/6fyph854
Dial in1-888-317-6003 (toll free) or 1-412-317-6061 (international)
Access Code0664356
CONFERENCE CALL REPLAY
Toll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)
International Toll1-412-317-0088
Replay Access Code3842515
Replay End DateFebruary 28, 2024
To access the replay using an international dial-in number, please select this link:
https://services.choruscall.com/ccforms/replay.html


An archived webcast will also be available on the Company's Investor Relations website under ?Past Events'.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter). 

Contacts:

Philippe Dubuc
Senior Vice President and Chief Financial Officer
[email protected]
438-315-6608



These press releases may also interest you

at 07:11
Author C.A. Blake was 24 years old when her brother, Steve, committed suicide. She struggled with the feeling she wouldn't survive the pain of it. Growing up in a time where little to no coping skills were taught or offered, she traveled the path of...

at 07:05
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor...

at 07:05
Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective...

at 07:05
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger...

at 07:05
bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder...

at 07:05
Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter...



News published on and distributed by: